Sangamo Therapeutics (STU:GBY) 3-Year Book Growth Rate : -65.30% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Sangamo Therapeutics 3-Year Book Growth Rate?

Sangamo Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was €0.10.

During the past 12 months, Sangamo Therapeutics's average Book Value per Share Growth Rate was -77.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was -65.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was -49.90% per year. During the past 10 years, the average Book Value per Share Growth Rate was -19.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Sangamo Therapeutics was 79.40% per year. The lowest was -65.30% per year. And the median was 1.15% per year.

Competitive Comparison of Sangamo Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Sangamo Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangamo Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

Sangamo Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Sangamo Therapeutics (STU:GBY) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Sangamo Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (STU:GBY) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

SGMO:USA 0R1D:UK GBY:Germany

Address

501 Canal Boulevard, Richmond, CA, USA, 94804

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Sangamo Therapeutics Headlines

No Headlines